ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

PEPG PepGen Inc

14.49
0.59 (4.24%)
After Hours
Last Updated: 06:00:49
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
PepGen Inc PEPG NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.59 4.24% 14.49 06:00:49
Open Price Low Price High Price Close Price Previous Close
14.00 13.41 14.59 14.49 13.90
more quote information »

Recent News

Date Time Source Heading
14/3/202407:05GLOBEPepGen to Participate in Upcoming Investor Conferences
13/3/202422:00GLOBEPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric..
07/3/202408:23EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07/3/202408:01GLOBEPepGen Reports Fourth Quarter and Full Year 2023 Financial..
07/3/202408:00EDGAR2Form 8-K - Current report
04/3/202423:27EDGAR2Form 8-K - Current report
04/3/202423:00GLOBEPepGen Announces Clearance of CTA by UK Medicines &..
02/3/202409:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/3/202409:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/3/202409:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202400:00EDGAR2Form 8-K - Current report
21/2/202400:00GLOBEPepGen Receives U.S. FDA Fast Track Designation for..
08/2/202408:55EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/2/202423:36EDGAR2Form 8-K - Current report
07/2/202423:30GLOBEPepGen Announces Pricing of $80.1 Million Underwritten..
18/1/202400:00EDGAR2Form 8-K - Current report
17/1/202423:00GLOBEMary Beth DeLena Joins PepGen as General Counsel and..
08/1/202423:00EDGAR2Form 8-K - Current report
08/1/202423:00GLOBEPepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase..
19/12/202300:00EDGAR2Form 8-K - Current report
19/12/202300:00GLOBEPepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1..
16/11/202300:00EDGAR2Form 8-K - Current report
16/11/202300:00GLOBEPepGen Announces Appointment of Howard Mayer, M.D. to Board..
09/11/202300:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202300:00EDGAR2Form 8-K - Current report
09/11/202300:00GLOBEPepGen Reports Third Quarter 2023 Financial Results and..
12/10/202322:52DJNFDA Lifts Hold on PepGen's New Drug Application for..
12/10/202322:05EDGAR2Form 8-K - Current report
12/10/202322:00GLOBEPepGen Inc. Announces FDA has Lifted the Clinical Hold on..
28/9/202306:16GLOBEPepGen Announces Upcoming Presentations at the 28th Annual..
07/9/202306:06EDGAR2Form 8-K - Current report
07/9/202306:05GLOBEPepGen Inc. Announces Clearance of CTA by Health Canada to..
06/9/202322:16EDGAR2Form 8-K - Current report
06/9/202322:00GLOBEPepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting..
01/9/202322:00GLOBEPepGen Announces Presentations at the 2023 Myotonic..
08/8/202322:49EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/8/202322:27EDGAR2Form 8-K - Current report
08/8/202322:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:15EDGAR2Form 8-K - Current report
08/8/202322:15GLOBEPepGen Reports Second Quarter 2023 Financial Results and..
14/6/202307:07DJNPepGen Withdraws Guidance on Launch of Study for Muscle..
14/6/202306:05GLOBEPepGen Inc. Provides Update on Planned Initiation of Phase 1..
31/5/202307:24DJNPepGen Shares Tumble 18.4% After FDA Issues Hold Notice on..
31/5/202306:05GLOBEPepGen Inc. Announces Clinical Hold in the U.S. on IND..
18/5/202321:00GLOBEPepGen Announces Clearance by Health Canada of CTA for..
11/5/202321:00GLOBEPepGen Reports First Quarter 2023 Financial Results and..
04/5/202322:00GLOBEPepGen to Participate in the Bank of America Securities 2023..

Your Recent History

Delayed Upgrade Clock